AU2021361057A1 - Malt1 modulators and uses thereof - Google Patents

Malt1 modulators and uses thereof Download PDF

Info

Publication number
AU2021361057A1
AU2021361057A1 AU2021361057A AU2021361057A AU2021361057A1 AU 2021361057 A1 AU2021361057 A1 AU 2021361057A1 AU 2021361057 A AU2021361057 A AU 2021361057A AU 2021361057 A AU2021361057 A AU 2021361057A AU 2021361057 A1 AU2021361057 A1 AU 2021361057A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
trifluoroethyl
μmol
triazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021361057A
Other languages
English (en)
Other versions
AU2021361057A9 (en
Inventor
Guillaume Barbe
Brian Addison DECHRISTOPHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rarefied Biosciences Inc
Original Assignee
Rarefied Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rarefied Biosciences Inc filed Critical Rarefied Biosciences Inc
Publication of AU2021361057A1 publication Critical patent/AU2021361057A1/en
Assigned to RAREFIED BIOSCIENCES, INC. reassignment RAREFIED BIOSCIENCES, INC. Request for Assignment Assignors: RHEOS MEDICINES, INC.
Publication of AU2021361057A9 publication Critical patent/AU2021361057A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Escalators And Moving Walkways (AREA)
  • Inspection Of Paper Currency And Valuable Securities (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AU2021361057A 2020-10-16 2021-10-15 Malt1 modulators and uses thereof Pending AU2021361057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092768P 2020-10-16 2020-10-16
US63/092,768 2020-10-16
PCT/US2021/055173 WO2022081967A1 (en) 2020-10-16 2021-10-15 Malt1 modulators and uses thereof

Publications (2)

Publication Number Publication Date
AU2021361057A1 true AU2021361057A1 (en) 2023-06-08
AU2021361057A9 AU2021361057A9 (en) 2025-03-20

Family

ID=81209361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021361057A Pending AU2021361057A1 (en) 2020-10-16 2021-10-15 Malt1 modulators and uses thereof

Country Status (7)

Country Link
US (1) US20230391781A1 (https=)
EP (1) EP4228647A4 (https=)
JP (1) JP7818011B2 (https=)
CN (1) CN116916924B (https=)
AU (1) AU2021361057A1 (https=)
CA (1) CA3198715A1 (https=)
WO (1) WO2022081967A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
EP4638458A1 (en) * 2022-12-23 2025-10-29 Janssen Pharmaceutica NV Malt1 inhibitors
WO2024182599A2 (en) * 2023-03-01 2024-09-06 Rarefied Biosciences, Inc. Compositions and methods for treating malt1 associated diseases
WO2025223516A1 (zh) * 2024-04-24 2025-10-30 首药控股(北京)股份有限公司 一种抑制剂杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5593996A (en) * 1991-12-30 1997-01-14 American Cyanamid Company Triazolopyrimidine derivatives
EP1644003A1 (en) * 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
WO2008065198A1 (en) * 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
SG11201607895PA (en) * 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
US10711036B2 (en) * 2015-08-28 2020-07-14 Cornell University MALT1 inhibitors and uses thereof
PE20190656A1 (es) * 2016-07-29 2019-05-08 Lupin Ltd Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3810609B1 (en) 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
TWI848400B (zh) * 2018-11-28 2024-07-11 日商武田藥品工業股份有限公司 雜環化合物及醫藥

Also Published As

Publication number Publication date
EP4228647A4 (en) 2024-09-11
EP4228647A1 (en) 2023-08-23
CA3198715A1 (en) 2022-04-21
AU2021361057A9 (en) 2025-03-20
JP7818011B2 (ja) 2026-02-19
CN116916924A (zh) 2023-10-20
CN116916924B (zh) 2026-02-27
US20230391781A1 (en) 2023-12-07
WO2022081967A1 (en) 2022-04-21
JP2023552002A (ja) 2023-12-13

Similar Documents

Publication Publication Date Title
JP7818011B2 (ja) Ｍａｌｔ１モジュレーターおよびその使用
EP4259631A1 (en) Imidazopyridazine derivatives as il-17 modulators
WO2022081995A1 (en) Malt1 modulators and uses thereof
WO2024182447A1 (en) Compounds and methods for modulating ras-pi3k
IL271104A (en) The traumatic compounds as inhibitors and fines
CN112654620B (zh) 用于治疗自身免疫性疾病的新型吡唑并吡啶化合物
AU2005262330A1 (en) Piperidine derivatives as NK1 antagonists
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
WO2020198583A1 (en) Bicyclic jak inhibitors and uses thereof
JP2026510921A (ja) Ｎｌｒｐ３を阻害するためのアミド誘導体及びその使用
RU2761626C2 (ru) ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
EP4499611B1 (en) Malt1 modulators and uses thereof
CA3247233A1 (en) T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A PIPERAZINE OR 1,4-DIAZEPANE CORE AND THEIR METHODS OF USE
JP2024532729A (ja) フェロトーシス調節物質、その調製及び使用
WO2024041397A1 (en) Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
WO2019016112A1 (en) SUBSTITUTED QUINOLINE COMPOUNDS IN POSITIONS 1, 2, 3 AND 4 AS MODULATORS OF S1P
EA048052B1 (ru) ПРОИЗВОДНЫЕ N-(ИМИДАЗО[1,2-b]ПИРИДАЗИН-3-ИЛ)-1-ЦИКЛОГЕКСИЛ-2H-ИНДАЗОЛ-5-КАРБОКСАМИДА И N-(ПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-ИЛ)-1-ЦИКЛОГЕКСИЛ-2H-ИНДАЗОЛ-5-КАРБОКСАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IRAK4 ДЛЯ ЛЕЧЕНИЯ АСТМЫ
JP2025539264A (ja) ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用
HK40102588B (en) N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma
HK40102588A (en) N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma
EA045845B1 (ru) Противовирусные средства для лечения и профилактики вич-инфекции
EA043370B1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RAREFIED BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): RHEOS MEDICINES, INC.

SREP Specification republished